Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

Med Clin (Barc). 2022 Oct 28;159(8):e54. doi: 10.1016/j.medcli.2022.04.018. Epub 2022 Jul 20.

[Article in English, Spanish]

Authors

Ismael F Aomar-Millán¹, Juan Salvatierra², Enrique Raya Álvarez²

Affiliations

¹ Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España; Instituto de investigación biosanitaria de Granada ibs.Granada, Granada, España. Electronic address: iaomarmillan@hotmail.com.
² Servicio de Reumatología, Hospital Universitario Clínico San Cecilio, Granada, España; Instituto de investigación biosanitaria de Granada ibs.Granada, Granada, España.

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
Standard of Care
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab